NO20020924D0 - Injiserbare buprenorphinmikropartikkelpreparater og deres anvendelse - Google Patents

Injiserbare buprenorphinmikropartikkelpreparater og deres anvendelse

Info

Publication number
NO20020924D0
NO20020924D0 NO20020924A NO20020924A NO20020924D0 NO 20020924 D0 NO20020924 D0 NO 20020924D0 NO 20020924 A NO20020924 A NO 20020924A NO 20020924 A NO20020924 A NO 20020924A NO 20020924 D0 NO20020924 D0 NO 20020924D0
Authority
NO
Norway
Prior art keywords
methadone
partial
opioid antagonist
opioid agonist
opioid
Prior art date
Application number
NO20020924A
Other languages
English (en)
Other versions
NO20020924L (no
NO322650B1 (no
Inventor
Thomas R Tice
Jay K Staas
Teresa M Ferrell
Peter Markland
Original Assignee
Southern Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southern Res Inst filed Critical Southern Res Inst
Publication of NO20020924D0 publication Critical patent/NO20020924D0/no
Publication of NO20020924L publication Critical patent/NO20020924L/no
Publication of NO322650B1 publication Critical patent/NO322650B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20020924A 1999-08-27 2002-02-26 Injiserbare buprenorfinmikropartikkelpreparater og deres anvendelse NO322650B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15111299P 1999-08-27 1999-08-27
PCT/US2000/023390 WO2001015699A1 (en) 1999-08-27 2000-08-25 Injectable buprenorphine microparticle compositions and their use

Publications (3)

Publication Number Publication Date
NO20020924D0 true NO20020924D0 (no) 2002-02-26
NO20020924L NO20020924L (no) 2002-04-03
NO322650B1 NO322650B1 (no) 2006-11-13

Family

ID=22537367

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20020924A NO322650B1 (no) 1999-08-27 2002-02-26 Injiserbare buprenorfinmikropartikkelpreparater og deres anvendelse
NO20063239A NO20063239L (no) 1999-08-27 2006-07-12 Injiserbare mikropartikkelpreparater

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20063239A NO20063239L (no) 1999-08-27 2006-07-12 Injiserbare mikropartikkelpreparater

Country Status (24)

Country Link
US (2) US6495155B1 (no)
EP (1) EP1212061B1 (no)
JP (1) JP4913298B2 (no)
KR (1) KR100730440B1 (no)
CN (2) CN1248689C (no)
AT (1) ATE280579T1 (no)
AU (1) AU765496C (no)
BR (1) BR0013650A (no)
CA (1) CA2382577C (no)
CY (1) CY1106043T1 (no)
CZ (1) CZ2002728A3 (no)
DE (1) DE60015370T2 (no)
EA (1) EA009080B1 (no)
ES (1) ES2230154T3 (no)
HK (1) HK1046858B (no)
HU (1) HUP0203613A3 (no)
IL (2) IL148343A0 (no)
MX (1) MXPA02002105A (no)
NO (2) NO322650B1 (no)
NZ (1) NZ517997A (no)
PL (1) PL198334B1 (no)
PT (1) PT1212061E (no)
RO (1) RO121631B1 (no)
WO (1) WO2001015699A1 (no)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001015699A1 (en) * 1999-08-27 2001-03-08 Southern Research Institute Injectable buprenorphine microparticle compositions and their use
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
AU2002303148A1 (en) * 2001-06-29 2003-03-03 Leon J. Lewandowski Individualized addiction cessation therapy
ES2385030T3 (es) * 2001-06-29 2012-07-17 Medgraft Microtech, Inc. Implantes inyectables biodegradables y procedimientos relacionados con su fabricación y uso
ATE376832T1 (de) * 2001-07-06 2007-11-15 Penwest Pharmaceuticals Co Verzögert freisetzende formulierungen von oxymorphon
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
DE60219478T2 (de) 2001-07-06 2008-01-03 Endo Pharmaceuticals Inc. Orale gabe von 6-hydroxy-oxymorphon als analgetikum
CA2459976A1 (en) * 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
US7462366B2 (en) 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
HUE039377T2 (hu) 2002-05-31 2018-12-28 L Molteni & C Dei Fratelli Alitti Soc Di Esercizio S P A Beültethetõ polimer eszköz buprenorfin folytonos kibocsátására
US7041320B1 (en) * 2002-05-31 2006-05-09 Biotek, Inc. High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence
US7842377B2 (en) * 2003-08-08 2010-11-30 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US8012454B2 (en) 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization
US7883490B2 (en) 2002-10-23 2011-02-08 Boston Scientific Scimed, Inc. Mixing and delivery of therapeutic compositions
WO2004078178A1 (en) * 2003-03-03 2004-09-16 Markus Heilig Buprenorphine compounds for treatment of alcohol dependence and excessive alcohol use
MXPA05010450A (es) 2003-03-31 2005-11-04 Titan Pharmaceuticals Inc Dispositivo polimerico implantable para la liberacion prolongada de agonistas de dopamina.
US7976823B2 (en) 2003-08-29 2011-07-12 Boston Scientific Scimed, Inc. Ferromagnetic particles and methods
US7901770B2 (en) 2003-11-04 2011-03-08 Boston Scientific Scimed, Inc. Embolic compositions
US7736671B2 (en) 2004-03-02 2010-06-15 Boston Scientific Scimed, Inc. Embolization
US8173176B2 (en) 2004-03-30 2012-05-08 Boston Scientific Scimed, Inc. Embolization
US7919499B2 (en) * 2004-04-22 2011-04-05 Alkermes, Inc. Naltrexone long acting formulations and methods of use
FR2869801B1 (fr) * 2004-05-05 2008-09-12 Ethypharm Sa Procede de preparation de compositions a liberation prolongee et utilisation de ces compositions pour le traitement des affections chroniques du systeme nerveux central (snc)
US7311861B2 (en) 2004-06-01 2007-12-25 Boston Scientific Scimed, Inc. Embolization
CN101076314A (zh) 2004-08-04 2007-11-21 克里纽沃药物有限公司 在对象体内诱导黑素生成的方法
US7727555B2 (en) 2005-03-02 2010-06-01 Boston Scientific Scimed, Inc. Particles
US7858183B2 (en) 2005-03-02 2010-12-28 Boston Scientific Scimed, Inc. Particles
US7963287B2 (en) 2005-04-28 2011-06-21 Boston Scientific Scimed, Inc. Tissue-treatment methods
US9463426B2 (en) 2005-06-24 2016-10-11 Boston Scientific Scimed, Inc. Methods and systems for coating particles
US20070141160A1 (en) * 2005-12-15 2007-06-21 Brown Laura J Method of treatment for osteoarthritis by local intra-articular injection of microparticles
US7947368B2 (en) 2005-12-21 2011-05-24 Boston Scientific Scimed, Inc. Block copolymer particles
US20080227805A1 (en) 2007-02-28 2008-09-18 Abbott Laboratories Sustained release parenteral formulations of buprenorphine
US8377479B2 (en) 2007-09-03 2013-02-19 Nanotherapeutics, Inc. Compositions and methods for delivery of poorly soluble drugs
US8728528B2 (en) * 2007-12-20 2014-05-20 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
US10933024B2 (en) 2008-09-24 2021-03-02 Evonik Operations Gmbh PH-dependent controlled release pharmaceutical composition for non-opioids with resistance against the influence of ethanol
CN104984343B (zh) * 2008-09-24 2019-04-02 赢创罗姆有限公司 耐受乙醇影响的非阿片类药物的pH依赖性受控释放的药物组合物
SI2341899T1 (sl) * 2008-09-24 2015-04-30 Evonik Roehm Gmbh Od pH odvisen opioidni farmacevtski sestavek z nadzorovanim sproščanjem z odpornostjo na vpliv etanola
US20100268191A1 (en) * 2009-04-21 2010-10-21 Medtronic Vascular, Inc. Drug Delivery Catheter using Frangible Microcapsules and Delivery Method
US9125867B2 (en) 2010-02-24 2015-09-08 Invincible Biotechnology Diversion- and/or abuse-resistant compositions and methods for making the same
GB2513060B (en) * 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
US9566241B2 (en) 2012-02-21 2017-02-14 Auburn University Buprenorphine nanoparticle composition and methods thereof
CA3120681A1 (en) 2012-04-17 2013-10-24 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CN102836131A (zh) * 2012-09-28 2012-12-26 山东大学 丁丙诺啡皮下注射用缓释微球制剂及其制备方法
US9636308B2 (en) 2013-03-15 2017-05-02 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
US9393211B2 (en) 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
JP6135292B2 (ja) * 2013-05-10 2017-05-31 ニプロ株式会社 マイクロカプセル製剤の製造方法
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
US11000520B2 (en) 2014-11-07 2021-05-11 Indivior Uk Limited Buprenorphine dosing regimens
AU2017223606A1 (en) 2016-02-23 2018-09-13 Biodelivery Sciences International, Inc. Sustained release buprenorphine microspheres (SRBM) and methods of use thereof
SG11201901294QA (en) 2016-09-13 2019-03-28 Alar Pharmaceuticals Inc Sustained-release buprenorphine formulations background of invention
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
WO2021028916A1 (en) * 2019-08-12 2021-02-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Pharmaceutical compositions comprising a combination of opioid antagonists

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4530840A (en) * 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4568559A (en) 1984-02-06 1986-02-04 Biotek, Inc. Composite core coated microparticles and process of preparing same
US4623588A (en) 1984-02-06 1986-11-18 Biotek, Inc. Controlled release composite core coated microparticles
GB8430346D0 (en) * 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
US5143661A (en) * 1987-05-26 1992-09-01 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules
FR2618674B1 (fr) 1987-07-30 1990-06-15 Ire Celltarg Sa Microparticules comportant un polymere biodegradable controlant la liberation d'un principe actif antimalarique, compositions pharmaceutiques en comprenant et procede de preparation
GB8728294D0 (en) 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US4902515A (en) * 1988-04-28 1990-02-20 E. I. Dupont De Nemours And Company Polylactide compositions
US5702716A (en) * 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
ATE133087T1 (de) 1989-05-04 1996-02-15 Southern Res Inst Einkapselungsverfahren
US5486362A (en) 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
AU2605592A (en) * 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5633000A (en) 1994-06-23 1997-05-27 Axxia Technologies Subcutaneous implant
US5716631A (en) 1995-09-29 1998-02-10 Rdn Therapeutics Inc. Long acting narcotic analgesics and antagonists
US5919473A (en) * 1997-05-12 1999-07-06 Elkhoury; George F. Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
WO2001015699A1 (en) * 1999-08-27 2001-03-08 Southern Research Institute Injectable buprenorphine microparticle compositions and their use

Also Published As

Publication number Publication date
CN1382051A (zh) 2002-11-27
IL148343A0 (en) 2002-09-12
NO20020924L (no) 2002-04-03
DE60015370D1 (de) 2004-12-02
US6495155B1 (en) 2002-12-17
JP4913298B2 (ja) 2012-04-11
JP2003508439A (ja) 2003-03-04
CA2382577C (en) 2008-01-22
NZ517997A (en) 2002-11-26
AU7075100A (en) 2001-03-26
MXPA02002105A (es) 2003-12-11
AU765496B2 (en) 2003-09-18
ATE280579T1 (de) 2004-11-15
HUP0203613A2 (hu) 2003-02-28
RO121631B1 (ro) 2008-01-30
BR0013650A (pt) 2002-05-07
KR100730440B1 (ko) 2007-06-19
HK1046858A1 (en) 2003-01-30
US20030152638A1 (en) 2003-08-14
CA2382577A1 (en) 2001-03-08
IL148343A (en) 2008-03-20
NO20063239L (no) 2002-04-03
EA200200295A1 (ru) 2002-08-29
DE60015370T2 (de) 2006-03-09
CZ2002728A3 (cs) 2002-08-14
EP1212061A1 (en) 2002-06-12
US7473431B2 (en) 2009-01-06
HUP0203613A3 (en) 2005-01-28
EA009080B1 (ru) 2007-10-26
PT1212061E (pt) 2005-01-31
CN100387228C (zh) 2008-05-14
AU765496C (en) 2005-08-25
KR20020053057A (ko) 2002-07-04
PL198334B1 (pl) 2008-06-30
EP1212061B1 (en) 2004-10-27
PL354977A1 (en) 2004-03-22
CY1106043T1 (el) 2011-04-06
HK1046858B (zh) 2005-03-24
CN1788721A (zh) 2006-06-21
NO322650B1 (no) 2006-11-13
WO2001015699A1 (en) 2001-03-08
ES2230154T3 (es) 2005-05-01
CN1248689C (zh) 2006-04-05

Similar Documents

Publication Publication Date Title
NO20020924L (no) Injiserbare buprenorfinmikropartikkelpreparater og deres anvendelse
HK1047245A1 (en) Injectable extented-release naltrexone microparticle compositions
WO1999011250A3 (en) Noribogaine in the treatment of pain and drug addiction
DE60234183D1 (de) Verwendung von methylnaltrexon zur behandlung von immunsuppression
ATE244558T1 (de) Trockene formbare arzneistoffformulierung
WO2003002175A8 (en) Enhanced systemic absorption of intradermally delivered substances
AU3638399A (en) Methods for preparation and use of tree injection nutrients and/or medicinal materials
EP1555023A3 (en) Injectable buprenorphine microparticle compositions and their use
AU2073602A (en) Use of weak opioids and mixed opioid agonists/antagonists for treating urinary incontinence
WO2002013759A3 (en) Method of treating the syndrome of type 2 diabetes in humans
HK1029277A1 (en) Pharmaceutical coating composition and method of use.
OELTGEN Characterization and utilization of opiate-like hibernation factors(Report, 15 Jul. 1992- 15 Dec. 1993)
Eggers et al. Tramadol hydrochloride--not just another opioid agonist.
Földes et al. Effects of methysergide, bromocriptine and naloxone on prolactin, growth hormone and TSH release induced by d-Met 2, Pro 5-enkephalinamide in man
Campi et al. ZT 52656A: EEG spectral analysis in freely-moving rats
AU2002232153A1 (en) Safe injector and injection needle for safe injector
WO2001074392A1 (fr) Preparations sous forme de microspheres contenant un antagoniste de recepteur de neurokinine 1
AUPS010302A0 (en) Subcutaneous implant or injection combining opiate agonists and antagonists
AUPR067600A0 (en) Improved single use syringe and syringe with retractable needle

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees